Get started
ReutersReuters

BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025

RefinitivLess than 1 min read
BCAB

Bioatla Inc BCAB:

  • BIOATLA PRESENTS PROMISING INTERIM DATA FROM ITS PHASE 1 TRIAL WITH BA3182 IN PATIENTS WITH TREATMENT REFRACTORY METASTATIC ADENOCARCINOMA AT ESMO 2025

North AmericaReutersUS stocks
refinitivrefinitiv
© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html
Login or create a forever free account to read this news

More news from Reuters